Navigation Links
BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Date:11/28/2011

NOVATO, Calif., Nov. 28, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA.  The facility will support up to $1.0 billion in revenue for BioMarin's growing enzyme replacement therapy portfolio, which is comprised of complex glycoprotein products produced by mammalian cells.  

"We are pleased with this first cycle approval of our manufacturing facility expansion which reflects our effective interactions with regulatory authorities and the high caliber of our technical operations team," stated Jean-Jacques Bienaime, Chief Executive Officer of BioMarin.  "BioMarin has a strong track record in manufacturing enzyme replacement therapies.  The approval of this facility supports the manufacturing requirements for anticipated peak sales of our commercial products and also supports several of our clinical and pre-clinical programs.  BioMarin's Novato manufacturing facilities are also producing clinical trial material for our pipeline protein products including, GALNS for MPS IV, PEG-PAL for PKU, our CNP analog for Achondroplasia and a new biologic to be disclosed at our upcoming R&D Day."

Mr. Bienaime continued, "The facility expansion will also be the initial site of commercial production for GALNS for MPS IVA, if pivotal Phase 3 results are positive in the second half of 2012. The next phase in our manufacturing capabilities expansion will occur in our recently purchased facility in Ireland.  Commercial production for some of our products in Ireland, including GALNS, will provide additional manufacturing diversity and assure adequate capacity for commercial demand of our current and future products."

The multi-product manufacturing plant in Novato was first licensed for pro
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin to Host a Research and Development Day on December 8th
2. BioMarin Announces Third Quarter 2011 Financial Results
3. BioMarin to Present at the UBS Global Life Sciences Conference
4. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
5. BioMarin to Present at the Baird Health Care Conference
6. BioMarin to Present at the Wedbush Life Sciences Conference
7. BioMarin Announces Second Quarter 2011 Financial Results
8. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
9. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
10. BioMarin to Present at the William Blair Growth Stock Conference
11. BioMarin to Present at the Jefferies Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAKE, N.J. and SAN DIEGO ... Inc. (NASDAQ: ARNA ) announced today that an ... 3 trials of lorcaserin entitled, "Early Weight Loss While on ... Weight-Loss Outcomes," was recently published in the online issue of ... Obesity Society. The objective of these analyses was to identify ...
(Date:7/30/2014)... DALLAS , July 30, 2014 /PRNewswire-iReach/ -- ... on Global and Chinese Heparin sodium (CAS 9041-08-1) ... reviews the basic information of Heparin sodium (CAS ... application and manufacturing technology. The report then explores ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) listing their ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a ... novel diagnostics to personalize and advance the treatment ... of a $30 million Series C Preferred Stock ... and Arcus Ventures, existing investors Domain Associates, Roche ... as undisclosed individual investors. With the proceeds of ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... NASHVILLE, Tenn., May 11, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... overview at the 2011 UBS Global Specialty Pharmaceuticals Conference ... p.m. The presentation will be simultaneously ...
... S.C., May 11, 2011 /PRNewswire-USNewswire/ -- ... announced that two client companies received big check investment ... Therapeutics and EnviroMix, both technology-based start-ups located in the ... technology and business model. Madeira Therapeutics was ...
Cached Medicine Technology:SC Launch Presents "Big Check" Investment to Two South Carolina Companies 2SC Launch Presents "Big Check" Investment to Two South Carolina Companies 3
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 “United States Orthopedic ... data on the United States Orthopedic Braces and Supports market. ... volume (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... Braces and Supports. , Orthotics is a specialty ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4
... released figures which show that there is an incredible ... for rehabilitation treatment programs under the banner of NHS(National ... . ,Most of the centers earmarked for drug ... the in- patient wards are empty and that referral ...
... floor spasm and pain, which may now be relieved by ... symptoms of this condition are heaviness, frequency or urgency in ... Abbott of the Royal Hospital For Women, Randwick conducted a ... effect of botox on women with pelvic spasms.30 women were ...
... Carnegie Mellon University conducted a path breaking study on ... in their ability to differentiate between living and non ... The paper which can be found in the Journal ... to one of the intriguing traits of autism: the ...
... The American College of Surgeons (ACS) has accredited NewYork-Presbyterian ... with the highest possible designation (1A),// in recognition of ... available. The top-level designation is a first for New ... ,An estimated 30 percent of U.S. adults 20 years ...
... a major recent countrywide study, antipsychotic drugs that are ... in treating Alzheimer's disease as most of the patients ... ,This study was conducted by Lon Schneider, professor ... the Keck School of Medicine of the University of ...
... develop pneumococcal pneumonia -- a common bacterial pneumonia that ... October issue of Mayo Clinic Women's HealthSource is spreading ... //against this form of pneumonia and reduces the serious ... unaware of the vaccine, or may not know that ...
Cached Medicine News:Health News:NHS De-addiction, Rehabilitation waiting time ticking into months 2Health News:Autistic Children May Lag behind in ‘Categorization of Objects 2Health News:NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery 2
Desmarres Lid Retractor thin solid blades. Size 2....
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... is a unique combination of Paradigm's ... flexibility for modular hardware modifications and ... of changing cataract surgical techniques and ... ophthalmic surgical platforms providing open architecture ...
Medicine Products: